The purpose of this study is to evaluate the risk of infections and malignancies among Rheumatoid Arthritis (RA) patients treated with Abatacept compared to other RA treatments.
Study Type
OBSERVATIONAL
Enrollment
100,000
Risk of Lung Cancer
The index date is defined as the date that the patient initiates Abatacept or a comparison anti-rheumatic drug
Time frame: Cancer: From 180 days after the index date until the first of the following: event of interest, death, or end of study (approximately 2 years)
Risk of lymphoma
The index date is defined as the date that the patient initiates Abatacept or a comparison anti-rheumatic drug
Time frame: Cancer: From 180 days after the index date until the first of the following: event of interest, death, or end of study (approximately 2 years)
Risk of breast cancer
The index date is defined as the date that the patient initiates Abatacept or a comparison anti-rheumatic drug
Time frame: Cancer: From 180 days after the index date until the first of the following: event of interest, death, or end of study (approximately 2 years)
Risk of non-melanoma skin cancer
The index date is defined as the date that the patient initiates Abatacept or a comparison anti-rheumatic drug
Time frame: Cancer: From 180 days after the index date until the first of the following: event of interest, death, or end of study (approximately 2 years)
Risk of all malignancies
The index date is defined as the date that the patient initiates Abatacept or a comparison anti-rheumatic drug
Time frame: Cancer: From 180 days after the index date until the first of the following: event of interest, death, or end of study (approximately 2 years)
Risk of hospitalized infections
The index date is defined as the date that the patient initiates Abatacept or a comparison anti-rheumatic drug
Time frame: Infection: From the index date until the first of the following: end of treatment +90 days, event of interest, death or end of study (approximately 1 year)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Risk of pneumonia
The index date is defined as the date that the patient initiates Abatacept or a comparison anti-rheumatic drug
Time frame: Infection: From the index date until the first of the following: end of treatment +90 days, event of interest, death or end of study (approximately 1 year)
Risk of opportunistic infections
The index date is defined as the date that the patient initiates Abatacept or a comparison anti-rheumatic drug
Time frame: Infection: From the index date until the first of the following: end of treatment +90 days, event of interest, death or end of study (approximately 1 year)
Risk of tuberculosis
The index date is defined as the date that the patient initiates Abatacept or a comparison anti-rheumatic drug
Time frame: Infection: From the index date until the first of the following: end of treatment +90 days, event of interest, death or end of study (approximately 1 year)
Incidence of lupus
The index date is defined as the date that the patient initiates Abatacept
Time frame: Outcomes will be assessed from 180 days after the index date until the first of the following: event of interest, death, or end of study (approximately 2 years)
Incidence of multiple sclerosis
The index date is defined as the date that the patient initiates Abatacept
Time frame: Outcomes will be assessed from 180 days after the index date until the first of the following: event of interest, death, or end of study (approximately 2 years)
Incidence of psoriasis
The index date is defined as the date that the patient initiates Abatacept
Time frame: Outcomes will be assessed from 180 days after the index date until the first of the following: event of interest, death, or end of study (approximately 2 years)